Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 4/2020

Ausgabe 4/2020

Inhaltsverzeichnis ( 30 Artikel )

02.08.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer – the role of STAT3 and p21

Chandra Bose Prabaharan, Allan Boyao Yang, Divya Chidambaram, Karthic Rajamanickam, Scott Napper, Meena Kishore Sakharkar

14.08.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

Identification of HGF as a novel target of miR-15a/16/195 in gastric cancer

Dongying Liu, Haiyang Zhang, Shaohua Ge, Dan Lin, Jiayi Han, Guoguang Ying, Yi Ba

20.08.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

Benzothiazole derivative bearing amide moiety induces p53-mediated apoptosis in HPV16 positive cervical cancer cells

Arusha Modi, Meenakshi Singh, Gopichand Gutti, Ozasvi R. Shanker, Vinay Kumar Singh, Sunita Singh, Sushil Kumar Singh, Satyajit Pradhan, Gopeshwar Narayan

24.08.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020 Open Access

Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines

Maximilian Hochmair, Barbara Rath, Lukas Klameth, Ernst Ulsperger, Christoph Weinlinger, Andreas Fazekas, Adelina Plangger, Robert Zeillinger, Gerhard Hamilton

28.08.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma

Xi’an Li, Guangdong Hou, Zheng Zhu, Fei Yan, Fuli Wang, Di Wei, Yu Zheng, Jiarui Yuan, Wanxiang Zheng, Geng Zhang, Ping Meng, Yan Guo, Xia Li, Libo Yao, Lan Shen, Jianlin Yuan

03.09.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

Radiosensitizing effects of trabectedin on human A549 lung cancer cells and HT-29 colon cancer cells

Katrin Manda, Tina Präkelt, Tonja Schröder, Stephan Kriesen, Guido Hildebrandt

06.09.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

A new series of acetohydroxamates shows in vitro and in vivo anticancer activity against melanoma

Gabriela C. Segat, Camila G. Moreira, Evelyn C. Santos, Melina Heller, Raquel C. Schwanke, Alexander V. Aksenov, Nicolai A. Aksenov, Dmitrii A. Aksenov, Alexander Kornienko, Rodrigo Marcon, João B. Calixto

13.09.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020 Open Access

Synthesis and cellular effects of novel 1,3,5-triazine derivatives in DLD and Ht-29 human colon cancer cell lines

Agnieszka Wróbel, Beata Kolesińska, Justyna Frączyk, Zbigniew J. Kamiński, Anna Tankiewicz-Kwedlo, Justyna Hermanowicz, Robert Czarnomysy, Dawid Maliszewski, Danuta Drozdowska

14.10.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3

Jingjie Sun, Yuping Du, Xinxin Zhang, Zhuoya Wang, Yuxi Lin, Qiaoling Song, Xiao Wang, Jihui Guo, Shanshan Li, Jing Nan, Jinbo Yang

24.10.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells

Toshimi Hoshiko, Yasushi Kubota, Takuya Akisawa, Tatsuro Watanabe, Kazuaki Tanigawara, Junichi Yano, Shinya Kimura

06.11.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

7-Chloroquinoline-1,2,3-triazoyl carboxamides induce cell cycle arrest and apoptosis in human bladder carcinoma cells

Mariana S. Sonego, Natália V. Segatto, Lucas Damé, Mariana Fronza, Carolina B. Gomes, Thais Larré Oliveira, Fabiana Kömmling Seixas, Lucielli Savegnago, Kyle M. Schachtschneider, Diego Alves, Tiago Collares

23.11.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2:V2-pemetrexed in lung adenocarcinoma Xenografts

Jingya Han, Yan Zhao, Xinming Zhao, Tuo Ma, Tiancheng Hao, Jiahui Liu, Zhaoqi Zhang, Jingmian Zhang, Jianfang Wang

28.11.2019 | PRECLINICAL STUDIES | Ausgabe 4/2020

Matteucinol, isolated from Miconia chamissois, induces apoptosis in human glioblastoma lines via the intrinsic pathway and inhibits angiogenesis and tumor growth in vivo

Ana Gabriela Silva, Viviane Aline O. Silva, Renato J. S. Oliveira, Allisson Rodrigues de Rezende, Rafael César Russo Chagas, Lúcia Pinheiro Santos Pimenta, Wanderson Romão, Hélio Batista Santos, Ralph Gruppi Thomé, Rui Manuel Reis, Rosy Iara Maciel de Azambuja Ribeiro

14.08.2019 | PHASE I STUDIES | Ausgabe 4/2020 Open Access

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma

Shunji Takahashi, Motohide Uemura, Tomokazu Kimura, Yoshihide Kawasaki, Atsushi Takamoto, Akito Yamaguchi, Amal Melhem-Bertrandt, Elaina M. Gartner, Takashi Inoue, Rio Akazawa, Takeshi Kadokura, Toshiki Tanikawa

30.08.2019 | PHASE I STUDIES | Ausgabe 4/2020 Open Access

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

Markus Joerger, Anastasios Stathis, Yannis Metaxas, Dagmar Hess, Mara Mantiero, Michael Mark, Matthias Volden, Thomas Kaindl, Marc Engelhardt, Patrice Larger, Heidi Lane, Peter Hafner, Nicole Levy, Silvia Stuedeli, Cristiana Sessa, Roger von Moos

10.09.2019 | PHASE I STUDIES | Ausgabe 4/2020

A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer

Rachel Goodwin, Derek Jonker, Eric Chen, Hagen Kennecke, Michael Cabanero, Ming-Sound Tsao, Michael Vickers, Caryn Bohemier, Howard Lim, Heather Ritter, Dongsheng Tu, Lesley Seymour

11.10.2019 | PHASE I STUDIES | Ausgabe 4/2020 Open Access

Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer

Jeroen Roosendaal, Hilde Rosing, Luc Lucas, Abadi Gebretensae, Alwin D. R. Huitema, Marloes G. van Dongen, Jos H. Beijnen, Aram Oganesian

21.10.2019 | PHASE I STUDIES | Ausgabe 4/2020

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)

Ruud van der Noll, Agnes Jager, Joo Ern Ang, Serena Marchetti, Marja W. J. Mergui-Roelvink, Johann S. de Bono, Martijn P. Lolkema, Maja J. A. de Jonge, Diane A. van der Biessen, Andre T. Brunetto, Hendrik-Tobias Arkenau, Ilian Tchakov, Jos H. Beijnen, Jacques De Grève, Jan H. M. Schellens

25.10.2019 | PHASE I STUDIES | Ausgabe 4/2020

Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma

Anthony Wood, Saby George, Nabil Adra, Sreenivasulu Chintala, Nur Damayanti, Roberto Pili

30.10.2019 | PHASE I STUDIES | Ausgabe 4/2020

Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)

Ruud van der Noll, Agnes Jager, Joo Ern Ang, Serena Marchetti, Marja W. J. Mergui-Roelvink, Martijn P. Lolkema, Maja J. A. de Jonge, Diane A. van der Biessen, Andre T. Brunetto, Hendrik-Tobias Arkenau, Ilian Tchakov, Jos H. Beijnen, Johann S. de Bono, Jan H. M. Schellens

07.11.2019 | PHASE I STUDIES | Ausgabe 4/2020

Epigallocatechin-3-gallate mouthwash protects mucosa from radiation-induced mucositis in head and neck cancer patients: a prospective, non-randomised, phase 1 trial

Wanqi Zhu, Hui Mei, Li Jia, Hanxi Zhao, Xiaolin Li, Xiangjiao Meng, Xianguang Zhao, Ligang Xing, Jinming Yu

09.11.2019 | PHASE I STUDIES | Ausgabe 4/2020

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

Sarah Lapointe, Warren Mason, Mary MacNeil, Craig Harlos, Roger Tsang, Joana Sederias, H. Artee Luchman, Samuel Weiss, John P. Rossiter, Dongsheng Tu, Lesley Seymour, Martin Smoragiewicz

09.11.2019 | PHASE I STUDIES | Ausgabe 4/2020

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

Johanna C. Bendell, Helge G. Bischoff, Jimmy Hwang, Hans Christian Reinhardt, Thomas Zander, Xuejing Wang, Scott Hynes, Celine Pitou, Robert Campbell, Philip Iversen, Daphne L. Farrington, Katherine Bell-McGuinn, Michael Thomas

16.11.2019 | PHASE I STUDIES | Ausgabe 4/2020

A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors

Albiruni R. Abdul Razak, Wilson H. Miller Jr, Geoffrey L. Uy, Steven Blotner, Anne-Marie Young, Brian Higgins, Lin-Chi Chen, Lia Gore

25.11.2019 | PHASE I STUDIES | Ausgabe 4/2020

Factors affecting symptom presentation in an early-phase clinical trials clinic patient population

Goldy C. George, Tito R. Mendoza, Eucharia C. Iwuanyanwu, Meryna Manandhar, Solmaz F. Afshar, Sarina A. Piha-Paul, Apostolia Tsimberidou, Aung Naing, Charles S. Cleeland, David S. Hong

10.12.2019 | PHASE I STUDIES | Ausgabe 4/2020 Open Access

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors

Toshihiko Doi, Nobuaki Matsubara, Akira Kawai, Norifumi Naka, Shunji Takahashi, Hiroji Uemura, Noboru Yamamoto

21.10.2019 | SHORT REPORT | Ausgabe 4/2020

Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients

Linlin Zhang, Liang Chen, Hao Yu

05.09.2019 | SHORT REPORT | Ausgabe 4/2020

Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report

Atsushi Matsunashi, Daichi Fujimoto, Kazutaka Hosoya, Kei Irie, Shoji Fukushima, Keisuke Tomii

24.10.2019 | SHORT REPORT | Ausgabe 4/2020

Prolonged response to 177Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor

Anne Ségolène Cottereau, Léopoldine Bricaire, Jennifer Arrondeau, Amina Dechmi, Françoise Montravers, Romain Coriat, Jerome Clerc, Lionel Groussin, Florence Tenenbaum

10.12.2019 | SHORT REPORT | Ausgabe 4/2020 Open Access

Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors

Yosuke Ando, Takahiro Hayashi, Reiko Sugimoto, Seira Nishibe, Kaori Ito, Kenji Kawada, Yoshiaki Ikeda, Shigeki Yamada, Kazuyoshi Imaizumi

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise